Skip to content

Psychiatric Genotype/Phenotype Project Repository

Psychiatric Genotype/Phenotype Project

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00762866
Acronym
PGPP
Enrollment
2000
Registered
2008-09-30
Start date
2008-09-01
Completion date
2027-12-01
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Depressive Disorder, Major, Psychotic Disorders

Keywords

Major Depressive Disorder, Depression, Bipolar I Disorder, Bipolar II Disorder, Bipolar Disorder NOS, Psychotic Disorder, Schizophrenia, Schizoaffective Disorder

Brief summary

The purpose of this project is to obtain DNA, brain imaging data, other biological samples (e.g., urine, serum), and a comprehensive clinical assessment on patients with schizophrenia and other psychotic disorders, bipolar disorder, major depression, and normal volunteer controls. Understanding the physical and genetic factors related to these disorders will help us make progress in fitting treatments to an individual's needs. Participants will take part in a detailed clinical assessment, two blood draws, and an MRI scan over two visits. Participants will also be asked to provide urine and saliva samples.

Detailed description

The links between psychiatric symptoms and underlying biological processes remain unclear at this time. Unipolar Major Depressive Disorder, Bipolar Disorder, and Schizophrenia are associated with major disruptions in functioning and quality of life. Understanding the causal physiological and genetic factors involved in each of these disorders would allow us to make great strides in tailoring treatment to the individual's needs. Because the etiology of these disorders are likely multifactorial in nature, a study examining a wide range of variables might best allow us to examine the interactions between different factors and to get a better sense of how genes and the brain interact to produce psychiatric disorder.

Interventions

None listed

Sponsors

Vanderbilt University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Between the ages of 16 and 65 2. Able and willing to provide informed consent 3. Able to read and speak English sufficiently to provide consent and answer questions 4. Diagnosis of one of the following: * Unipolar Major Depressive Disorder of any subtype * Bipolar I, Bipolar II Disorder, or Bipolar Disorder NOS * Axis I Psychotic Disorder, which can include the diagnoses of Schizophrenia, Schizoaffective Disorder, Major Depression or Mania with Psychotic Features, Schizophreniform Disorder, Brief Psychotic Episode, or Psychotic Disorder NOS * Normal volunteer controls, individuals with no personal history of any Axis I disorder.

Exclusion criteria

1. Reported pregnancy or breastfeeding 2. Dementia or delirium 3. Any medical condition that would interfere with participation in the study. This would include, but not be limited to: * uncontrolled diabetes, hypothyroidism, Cushing's disease, or other significant endocrine condition (treated endocrine condition is allowed) * demyelinating disease * HIV infection * active hepatitis * CNS infection * clinically significant and unstable cardiovascular disease * any cancer involving the CNS (including metastatic disease) 4.

Design outcomes

Primary

MeasureTime frameDescription
Brain volume2 yearsObservational neuromaging study

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORStephan Heckers, M.D.

Vanderbilt University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026